With time running out for the 2007 session of the 110th Congress, Generic Pharmaceutical Association (GPhA) leaders called on lawmakers to step up efforts to enact legislation that would streamline the approval of lower-cost generic versions of biological products. ?For the countless Americans who are in need of safe and affordable lifesaving biogenerics, it is imperative that Congress continue to move legislation forward,? GPhA President and Chief Executive Officer Kathleen Jaeger said during the association?s Annual Policy Conference in Washington. ?We?ve come a long way in a short period of time, but we still need to cross the finish line.?
The bill supported by GPhA has also drawn backing from more than 70 other organizations that consider it important to lower the cost of biologicals. If the bill fails to clear the current Congress before adjournment, the issue could emerge as a priority for candidates during next fall?s national elections.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs